You can buy or sell Pulmatrix and other stocks, options, ETFs, and crypto commission-free!
Pulmatrix, Inc. Common Stock, also called Pulmatrix, is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. Read More The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
52 Week High
52 Week Low
Seeking AlphaMar 20
Pulmatrix files for equity offering
Pulmatrix (NASDAQ:PULM) has filed a preliminary prospectus for a public offering of stock and warrants. Prices, volumes and terms have yet to be released...
Markets InsiderMar 14
Pulmatrix to Participate in Upcoming Investor Conferences
LEXINGTON, Mass., March 14, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) announced today that members of its management team will present/participate in investor meetings at the following upcoming conferences: Oppenheimer's 29th Annual Healthcare Conference Date: Tuesday, March 19, 2019 Presentation Time: 4:30 PM ET Speaker: Ted Raad, Chief Business Officer Location: New York, NY 31st Annual ROTH Conference Date: Tuesday, March 19, 2019 Participate in Investor Meetings (1x1): Robert W. Clar...
Yahoo FinanceMar 8
These Four Tech Stocks Could Set The Pace On Friday
CORAL GABLES, FL / ACCESSWIRE / March 8, 2019 / The future of tech stock market is dependent on whether companies in the tech industry are prepared to meet the growing demands of society with innovative technologies and creative solutions.
Expected May 10, Pre-Market